Lawmakers in Connecticut are making sure they’re not caught flat-footed if psychedelic therapy gets the federal green light.
According to reporting from Marijuana Moment, state legislators have approved a bill to expand Connecticut’s existing psychedelics pilot program—positioning the state ahead of potential approval from the Food and Drug Administration (FDA).
The updated measure broadens who can participate. Previously focused largely on veterans and first responders, the program would now be open to adults 18 and older who meet clinical criteria set by researchers overseeing the studies. In short: more data, more access, fewer artificial limits.
Lawmakers also cleaned up language that would have automatically shut down the pilot if the FDA approves substances like psilocybin or MDMA for medical use. Instead of pulling the plug once Washington acts, Connecticut wants the flexibility to keep researching, refining, and expanding treatment options.
Another tweak removes an outdated deadline that required the state’s Department of Mental Health and Addiction Services to stand the program up by a specific date—because nothing says “serious medical research” like racing a bureaucratic clock.
The message from lawmakers is clear: if psychedelic-assisted therapy becomes federally approved, Connecticut intends to be ready—not scrambling.
While some states are still debating whether to dip a toe in the psychedelic waters, Connecticut appears to be packing a surfboard.
Dabbin-Dad Newsroom
